Krystal Biotech

Krystal Biotech is a biotechnology company focused on the development and commercialization of gene therapies for patients with rare diseases. The company's lead product candidate is VYJUVEK® (beremagene geperpavec-svdt), a topical gene therapy for the treatment of dystrophic epidermolysis bullosa (DEB), a rare and severe genetic skin disease. VYJUVEK is the first-ever redosable gene therapy and the first and only medicine approved by the FDA for the treatment of DEB, for which the company holds exclusive worldwide rights.

Krystal Biotech's business model revolves around its proprietary STAR-D gene therapy platform, which enables the development of off-the-shelf treatments for a wide range of dermatological diseases. The company's revenue is primarily generated from the sale of VYJUVEK. Krystal Biotech serves a niche market of patients with rare dermatological conditions, working closely with healthcare professionals and patient advocacy groups to provide access to its treatments. The company is publicly traded on the Nasdaq stock exchange under the ticker symbol KRYS.

Keywords: gene therapy, rare diseases, dermatology, VYJUVEK, dystrophic epidermolysis bullosa, STAR-D platform, redosable, topical treatment, genetic skin disease, orphan drugs